Innovating Works

ITFoM

Financiado
IT Future of Medicine Data-rich, individualised medicine poses unprecedented challenges for IT, in hardware, storage and communication. We propose a data-driven, individualised medicine of the future, based on molecular/physiological/anatomical data fr... Data-rich, individualised medicine poses unprecedented challenges for IT, in hardware, storage and communication. We propose a data-driven, individualised medicine of the future, based on molecular/physiological/anatomical data from individual patients. We shall make general models of human pathways, tissues, diseases and ultimately of the human as a whole. Individualised versions of the models, produced for each patient, will then be used to identify personalised prevention/therapy schedules and side effects of drugs.<br/>To develop this IT driven, data rich, individualised medicine of the future, this first-phase flagship project will prepare for the amalgamation of 5 major areas: medicine, from sample and diagnosis provision to clinical practice and patient consent, analytical techniques, covering functional genomics and imaging technology analyses on a routine basis, IT developments required to address the computational challenges, and integration, developing interfaces, modelling and machine learning tools required to integrate the data generated through the different analysis streams, and to inform relevant health providers. A coordination work package will address the administrative, educational, funding and translational components of the work.<br/>This is the first time the huge IT implications of worldwide individualized patient care will be addressed and combined with up-to-date genomics and requirements from the medical field. The project outcomes will enable the calculation of health, disease, therapy and its effects for individual patients. These may revolutionize our health care with enormous (i) benefits for health (prevention, diagnosis and therapy), (ii) reduction in health care cost by individualising combinations of a limited number of drugs, and (iii) new commercial opportunities in the IT, analytic and health care sectors. ver más
30/04/2012
MAXPLANCKGESELLSCHAFT ZUR...
2M€
Duración del proyecto: 11 meses Fecha Inicio: 2011-05-01
Fecha Fin: 2012-04-30

Línea de financiación: concedida

El organismo FP7 notifico la concesión del proyecto el día 2012-04-30
FP7 No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE... No se ha especificado una descripción o un objeto social para esta compañía.